KR960010683A - 소마토스타틴 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물 - Google Patents

소마토스타틴 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR960010683A
KR960010683A KR1019950028905A KR19950028905A KR960010683A KR 960010683 A KR960010683 A KR 960010683A KR 1019950028905 A KR1019950028905 A KR 1019950028905A KR 19950028905 A KR19950028905 A KR 19950028905A KR 960010683 A KR960010683 A KR 960010683A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
radionuclide
complex
pharmaceutically acceptable
Prior art date
Application number
KR1019950028905A
Other languages
English (en)
Other versions
KR100364111B1 (ko
Inventor
알버트 라이너
브룬스 크리스티안
스미스-존즈 페터
스톨츠 바바라
베크베커 기스버트
Original Assignee
페. 래스·에이치. 알. 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페. 래스·에이치. 알. 하우스, 산도즈 리미티드 filed Critical 페. 래스·에이치. 알. 하우스
Publication of KR960010683A publication Critical patent/KR960010683A/ko
Application granted granted Critical
Publication of KR100364111B1 publication Critical patent/KR100364111B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

유리 형태 또는 염 형태인 하기 일반식(Ⅰ)의 화합물은 α선-또는 β선-방출 방사성핵종 또는 오오제-전자-캐스캐이드를 가지는 핵종과 착화합물을 형성했을때 방사성 의약품으로서 유용하다.
상기 식에서, M은 양이온 등가물이고, A는 페닐알라닌 또는 타이로신이다.

Description

소마토스타딘 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 유리 형태, 염 형태 또는 방사성 핵종과 착화합된 형태의 일반식(Ⅰ)의 화합물.
    상기 식에서, M은 양이온이고, A는 페닐알라닌 또는 타이로신이다.
  2. 제1항에 있어서, A가 타이로신인 화합물.
  3. 제1항에 또는 제2항에 있어서,90Y또는161Tb와 착화합물을 형성한 화합물.
  4. 제1항에 있어서,M이 H+인 화합물.
  5. 방사성핵종과 착화합물을 형성한 제1항의 일반식 (Ⅰ)의 화합, 또는 그 약학적 허용염을 포함하고, 하나 이상의 약학적 허용 담체 및 회석제를 포함하는 소마토스타틴 수용테 양성인 종양 및 그 전이부 치료용 약학조성물.
  6. 제5 항에 있어서, 부가적으로 안정화제를 포함하는 약학 조성물.
  7. 제6항에 있어서, 안정화제가 혈청 알부민, 아스코르빈산, 레티놀, 겐티신산 또는 그 유도체, 및 아미노산 용액으로 이루어진 그룹중에서 선택되는 특징으로 하는 약학 조성물.
  8. 60내지 120℃의 온도에서 방사성핵종-산출 화합물과 일ㄹ반식(Ⅰ)의 화합물을 반응시키는 단계로 구성되는 제1항의 일반식(Ⅰ)이 화합물과 방사성핵종을 착화합시키는 방법.
  9. 방사성핵종과 착화합물을 형성한 일반식(Ⅰ)의 화합물, 또는 그 약학적 허용염을 포함하는 약학 조성물을 함유하면서 추가로 세포증식 억제제를 포함하는 하나 이상의 약학 조성물을 함유하는 종양 침윤성 및 종양 성장과 관련된 증후군 치료용 조합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950028905A 1994-09-06 1995-09-05 소마토스타틴펩타이드,이의제법및이를함유하는약학적조성물 KR100364111B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417873A GB9417873D0 (en) 1994-09-06 1994-09-06 Organic compounds
GB9417873.8 1994-09-06

Publications (2)

Publication Number Publication Date
KR960010683A true KR960010683A (ko) 1996-04-20
KR100364111B1 KR100364111B1 (ko) 2003-02-05

Family

ID=10760870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950028905A KR100364111B1 (ko) 1994-09-06 1995-09-05 소마토스타틴펩타이드,이의제법및이를함유하는약학적조성물

Country Status (31)

Country Link
US (2) US6183721B1 (ko)
EP (1) EP0714911B1 (ko)
JP (1) JP3054346B2 (ko)
KR (1) KR100364111B1 (ko)
CN (1) CN1185252C (ko)
AT (1) ATE199561T1 (ko)
AU (1) AU703057B2 (ko)
BR (1) BR9503936A (ko)
CA (1) CA2157530C (ko)
CO (1) CO4410344A1 (ko)
CZ (1) CZ287012B6 (ko)
DE (1) DE69520256T2 (ko)
DK (1) DK0714911T3 (ko)
ES (1) ES2157309T3 (ko)
FI (1) FI117424B (ko)
GB (1) GB9417873D0 (ko)
GR (1) GR3035997T3 (ko)
HU (1) HU218284B (ko)
IL (1) IL115154A (ko)
NO (1) NO316569B1 (ko)
NZ (1) NZ272919A (ko)
PE (1) PE41496A1 (ko)
PL (1) PL182434B1 (ko)
PT (1) PT714911E (ko)
RU (1) RU2156774C2 (ko)
SG (1) SG50356A1 (ko)
SI (1) SI0714911T1 (ko)
SK (1) SK283774B6 (ko)
TR (1) TR199501094A2 (ko)
TW (1) TW387898B (ko)
ZA (1) ZA957475B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
LT3351246T (lt) 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
IL157359A0 (en) * 2001-02-26 2004-02-19 Bristol Myers Squibb Pharma Co A radiopharmaceutical composition containing an ascorbic acid analog
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
AU2003250658B2 (en) 2002-07-18 2009-07-16 Helix Biopharma Corp. Use of urease for inhibiting cancer cell growth
WO2004081031A2 (en) * 2003-03-10 2004-09-23 Biogen Idec Inc. Thiol-mediated drug attachment to targeting peptides
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20100029911A1 (en) * 2004-11-24 2010-02-04 Aplagen Gmbh Method For Solid-Phase Peptide Synthesis And Purification
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20140170068A1 (en) 2011-03-11 2014-06-19 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
CN103275189B (zh) * 2013-06-06 2014-08-06 深圳翰宇药业股份有限公司 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2018044812A2 (en) 2016-08-29 2018-03-08 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
ES2960030T3 (es) 2017-01-12 2024-02-29 Radiomedix Inc Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos
TW202017600A (zh) * 2018-06-21 2020-05-16 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202015744A (zh) 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CA3188728A1 (en) 2020-08-07 2022-02-10 Marc Nasoff Immunoconjugates targeting cd46 and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006643A (en) 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
DE3728600A1 (de) 1987-08-27 1989-03-09 Hoechst Ag Verfahren zur markierung von substanzen mit technetium oder rhenium
AU630362B2 (en) * 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
CA2066031C (en) 1989-09-29 2001-02-27 Mary A. Gray Methods for reducing non-target retention of immunoconjugates and metabolites thereof
WO1993018797A1 (en) * 1992-03-25 1993-09-30 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
CA2113121A1 (en) * 1993-01-12 1994-07-13 Rainer Albert Peptides
EP0738158B1 (en) * 1994-01-12 2002-04-03 Amersham plc Biological targeting agents
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
PL182434B1 (pl) 2002-01-31
CA2157530A1 (en) 1996-03-07
HU218284B (en) 2000-07-28
TR199501094A2 (tr) 1996-06-21
AU703057B2 (en) 1999-03-11
GR3035997T3 (en) 2001-09-28
US6183721B1 (en) 2001-02-06
FI117424B (fi) 2006-10-13
ES2157309T3 (es) 2001-08-16
SK283774B6 (sk) 2004-01-08
CN1127259A (zh) 1996-07-24
PE41496A1 (es) 1996-10-14
PL310274A1 (en) 1996-03-18
CO4410344A1 (es) 1997-01-09
SI0714911T1 (en) 2001-08-31
PT714911E (pt) 2001-08-30
NO953457D0 (no) 1995-09-04
CA2157530C (en) 2007-04-03
TW387898B (en) 2000-04-21
ZA957475B (en) 1997-03-06
RU2156774C2 (ru) 2000-09-27
CZ226395A3 (en) 1996-03-13
KR100364111B1 (ko) 2003-02-05
DK0714911T3 (da) 2001-07-09
FI954147A (fi) 1996-03-07
JPH0881498A (ja) 1996-03-26
NO953457L (no) 1996-03-07
SK108895A3 (en) 1996-06-05
IL115154A0 (en) 1995-12-31
GB9417873D0 (en) 1994-10-26
DE69520256D1 (de) 2001-04-12
NO316569B1 (no) 2004-02-23
FI954147A0 (fi) 1995-09-04
CZ287012B6 (en) 2000-08-16
DE69520256T2 (de) 2001-08-09
HU9502577D0 (en) 1995-11-28
ATE199561T1 (de) 2001-03-15
SG50356A1 (en) 2000-11-21
NZ272919A (en) 1996-12-20
EP0714911B1 (en) 2001-03-07
EP0714911A2 (en) 1996-06-05
IL115154A (en) 2000-08-13
US6277356B1 (en) 2001-08-21
CN1185252C (zh) 2005-01-19
EP0714911A3 (en) 1996-08-21
AU3041495A (en) 1996-03-21
BR9503936A (pt) 1996-09-24
HUT72895A (en) 1996-06-28
JP3054346B2 (ja) 2000-06-19

Similar Documents

Publication Publication Date Title
KR960010683A (ko) 소마토스타틴 펩타이드, 이의 제법 및 이를 함유하는 약학적 조성물
DK326785A (da) Terapeutisk middel til paavisning og/eller behandling af tumorer og fremgangsmaade til fremstilling af et saadant middel
RU95114740A (ru) Пептиды
ES8401977A1 (es) Procedimiento para preparar nuevos compuestos de cefem.
NO995160D0 (no) Fremgangsmåte for fremstilling av overflate metall trikarbonylforbindelser og deres bruk i merking av biologisk aktive substrater
GB1481219A (en) Preparation of benzodiazepines
DE3372764D1 (en) Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them
KR830007092A (ko) 방사성 진단제 및 그의 비-방사성 담체
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
DE3661918D1 (en) Organosilanes containing phenylene groups, process for their preparation
DK171487A (da) Spergualinderivater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
KR840006254A (ko) 7-치환된-3-비닐-3-세펨화합물의 제조방법
EP0281412A3 (en) Novel organic platinum complex pharmaceutical compositions containing same and a process for the preparation thereof
GB1493684A (en) S-substituted-2-thiodenosines
US4925925A (en) Radioactive rhenium ligated to 2-hydroxy isobutyric acid and method of use
ATE41769T1 (de) Immunwirksame verbindungen.
GB1243953A (en) Benzdiazepine derivatives
NO931671L (no) Depot-preparat
KR840005107A (ko) 피리미디온 및 그의 산부가염의 제조방법
Henderson et al. Irreversible inhibition of folate transport in Lactobacillus casei by covalent modification of the binding protein with carbodiimide-activated folate
SE7412147L (ko)
GB1449078A (en) Phenoxyethylamine derivatives
KR860001815A (ko) 옥타하이드로-옥사졸로[4,5-g]퀴놀린의 제조방법
KR960000250A (ko) 종양친화성펩티드와 이를 함유하는 방사성진단제 및 방사성치료제
EP0223512A3 (en) 2-pyridylacetic acid derivative, preparation process thereof and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131101

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20141107

Year of fee payment: 13

EXPY Expiration of term